Semaglutide 2mg

Name: Semaglutide 2mg
SKU: PL-2MG-PL01
Price: 110.00 USD
Availability: InStock

Brands PeptideLion

$110.00

out of stock

Sku:

PL-2MG-PL01

Brands: PeptideLion

Description

Overview:

What is Semaglutide?

Semaglutide belongs to a class of medications known as glucagon-like peptide-1 receptor agonists, or GLP-1 RAs. It mimics the GLP-1 hormone, released in the gut in response to eating. One role of GLP-1 is to prompt the body to produce more insulin, which reduces blood sugar (glucose). For that reason, healthcare providers have used semaglutide for more than 15 years to treat Type 2 diabetes.

But GLP-1 in higher amounts also interacts with the parts of the brain that suppress your appetite and signal you to feel full. When used in conjunction with diet and exercise, it can cause significant weight loss — and a reduced risk of cancer, diabetes, and heart disease — in people who are obese or overweight.

Who Is a Good Candidate for Semaglutide?

“A good candidate for Ozempic is someone comfortable providing a weekly self-injection, has a medical history of type 2 diabetes, and an elevated body mass index (BMI) of at least 27,” says Dr. Saunders. Similarly, a good candidate for Rybelsus has a medical history of type 2 diabetes and a BMI of 27 or more, she says.

A good candidate for Wegovy must also be comfortable with a weekly self-injection and have a BMI of 30 (with or without weight-related health complications) or a BMI of at least 27 with at least one weight-related health complication (like high cholesterol or hypertension), explains Dr. Saunders.

Scientific Information:

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is available as monotherapy in both subcutaneous and oral forms (the first approved oral GLP-1 receptor agonist). The FDA has approved it as a second-line treatment for better glycemic control in type 2 diabetes, and researchers are currently investigating its potential for anti-obesity purposes. Studies have proven semaglutide safe for adults and elderly patients with renal or hepatic disorders, requiring no dose adjustments. Cardiovascular (CV) outcome trials show that it can reduce various CV risk factors in patients with existing CV conditions. While semaglutide is well-tolerated and carries no risk of hypoglycemia in monotherapy, it does cause some gastrointestinal adverse effects.

A large population affected with COVID-19 infection were diabetic; therefore, the use of semaglutide in diabetes as well as CV patients would be very supportive in maintaining the healthcare system during this pandemic situation. Hence, this peptidic drug can be truly considered a quintessential GLP-1 agonist for the management of type 2 diabetes.

Research Highlights:

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that works by mimicking the activity of GLP-1, a hormone released in the intestine after eating. GLP-1 triggers insulin production, thereby reducing blood sugar levels, and interacts with parts of the brain to decrease hunger and promote feelings of satiety. Different forms of semaglutide are FDA-approved for treating type 2 diabetes or obesity (in conjunction with diet and exercise).

If you are obese, overweight, or struggling to lose weight, semaglutide, a simple peptide, could be a game-changer. This GLP-1 receptor agonist (RA) mimics the GLP-1 hormone released in the digestive system. As a result, it suppresses appetite, which, when combined with a healthier diet and exercise, can lead to weight loss. It is also the first drug in seven years that the FDA has approved for treating obesity, marking a significant achievement. Semaglutide outperforms other GLP-1 RAs in improving glycemia and other cardio-metabolic risk factors in individuals with T2DM.